Dolutegravir-based ART is superior to NNRTI- and PI-based ART in infants, children and adolescents living with HIV (combined results of the main trial and the ‘under 14kg’ cohort)

29 Jul, 2021

Authors: Turkova A on behalf of the ODYSSEY trial team     

Presented at: CHIVA 2021